Stock 603229 ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Zhejiang Ausun Pharmaceutical Co., Ltd. Stock

Equities

603229

CNE100002XK2

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-22 pm EDT 		5-day change 1st Jan Change
9.99 CNY +0.60% Intraday chart for Zhejiang Ausun Pharmaceutical Co., Ltd. +4.61% -24.38%
2023 Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
2023 Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Financials

Sales 2023 * 925M 128M Sales 2024 * 1.16B 161M Capitalization 5.92B 818M
Net income 2023 * 305M 42.1M Net income 2024 * 387M 53.42M EV / Sales 2023 * 6.41 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 5.09 x
P/E ratio 2023 *
19.4 x
P/E ratio 2024 *
15.3 x
Employees 1,129
Yield 2023 *
1.5%
Yield 2024 *
1.9%
Free-Float 40.03%
More Fundamentals * Assessed data

Chart Zhejiang Ausun Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Zhejiang Ausun Pharmaceutical Co., Ltd.

Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhejiang Qizheng Pharmaceutical Co., Ltd. announced that it has received CNY 20 million in funding from Zhejiang Ausun Pharmaceutical Co., Ltd. CI
Ausun Pharma's Unit Passes Regulatory Inspection MT
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhejiang Qizheng Pharmaceutical Co., Ltd. announced that it expects to receive CNY 20 million in funding from Zhejiang Ausun Pharmaceutical Co., Ltd. CI
Zhejiang Ausun Pharma Sees Up to 70% Jump in 2022 Profit; Shares Rose 4% MT
Zhejiang Ausun Pharma Gets Regulatory Nod to Market Azvudine MT
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it has received CNY 484.90308 million in funding from Gongqingcheng Shengheng Investment Management Co., Ltd., Shanghai Panjing Investment Management Center (Limited Partnership), Taizhou Financial Holding Asset Management Co., Ltd., and other investors CI
Marvel Biosciences Completes Manufacturing Milestone Ahead of Phase 1 Trials Targeting Alzheimer's Disease, Depression MT
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Ausun Pharmaceutical Co., Ltd.(XSSC:603229) added to S&P Global BMI Index CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study MT
More news

Quotes and Performance

1 day+0.60%
1 week+4.61%
Current month-1.67%
1 month-8.01%
3 months-8.35%
6 months-26.65%
Current year-24.38%
More quotes

Highs and lows

1 week
9.35
Extreme 9.35
10.09
1 month
9.35
Extreme 9.35
10.88
Current year
8.06
Extreme 8.06
13.35
1 year
8.06
Extreme 8.06
17.47
3 years
8.06
Extreme 8.06
47.90
5 years
3.56
Extreme 3.5593
47.90
10 years
3.08
Extreme 3.0825
47.90
More quotes

Managers and Directors - Zhejiang Ausun Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Zhi Guo Zheng CEO
 Chief Executive Officer 53 14-12-14
Ding Min Zhu DFI
 Director of Finance/CFO 57 21-11-01
Hua Dong Zhang BRD
 Director/Board Member 47 14-12-13
Members of the board TitleAgeSince
Fei Chen BRD
 Director/Board Member 44 15-01-07
Zhi Guo Zheng CEO
 Chief Executive Officer 53 14-12-14
Zhi Shu Yang BRD
 Director/Board Member 58 20-12-12
More insiders

ETFs positioned on Zhejiang Ausun Pharmaceutical Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.14% -
More ETFs positioned on Zhejiang Ausun Pharmaceutical Co., Ltd.

Quotes

Date Price Change Volume
24-04-23 9.99 +0.60% 5,152,012
24-04-22 9.93 +3.98% 6,445,888
24-04-19 9.55 -1.85% 5,443,886
24-04-18 9.73 -2.41% 5,144,100
24-04-17 9.97 +4.40% 5,178,890

End-of-day quote Shanghai S.E., April 22, 2024

More quotes

Company Profile

Zhejiang Ausun Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of specialty bulk pharmaceutical chemicals (BPCs) and pharmaceutical intermediates. The Company's main products include bimatoprost, latanoprost, latanoprostene bunod, entecavir, selectfluor and other intermediates. The Company is also involved in the provision of customized production, as well as research and development services to customers through its subsidiaries.
Sector
Pharmaceuticals
Calendar
2024-04-26 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Ausun Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
9.99
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. Stock Zhejiang Ausun Pharmaceutical Co., Ltd.
-24.38% 813M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.92% 659B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.68% 557B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.59% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.38% 322B
ABBVIE INC. Stock AbbVie Inc.
+9.39% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+6.30% 215B
NOVARTIS AG Stock Novartis AG
+4.80% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-6.05% 200B
PFIZER, INC. Stock Pfizer, Inc.
-8.58% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 603229 Stock